- Home
- EXPE vs BIIB Comparison
EXPE vs BIIB Comparison
Compare EXPE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXPE
- BIIB
- Stock Information
- Founded
- EXPE 1996
- BIIB 1978
- Country
- EXPE United States
- BIIB United States
- Employees
- EXPE N/A
- BIIB N/A
- Industry
- EXPE Transportation Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- EXPE Consumer Discretionary
- BIIB Health Care
- Exchange
- EXPE Nasdaq
- BIIB Nasdaq
- Market Cap
- EXPE 22.6B
- BIIB 18.7B
- IPO Year
- EXPE 1999
- BIIB 1991
- Fundamental
- Price
- EXPE $207.44
- BIIB $138.60
- Analyst Decision
- EXPE Buy
- BIIB Buy
- Analyst Count
- EXPE 26
- BIIB 27
- Target Price
- EXPE $201.13
- BIIB $188.09
- AVG Volume (30 Days)
- EXPE 2.1M
- BIIB 1.5M
- Earning Date
- EXPE 08-07-2025
- BIIB 07-31-2025
- Dividend Yield
- EXPE 0.77%
- BIIB N/A
- EPS Growth
- EXPE 45.71
- BIIB 31.67
- EPS
- EXPE 8.24
- BIIB 10.45
- Revenue
- EXPE $14,018,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- EXPE $5.62
- BIIB N/A
- Revenue Next Year
- EXPE $6.29
- BIIB N/A
- P/E Ratio
- EXPE $25.17
- BIIB $13.26
- Revenue Growth
- EXPE 5.69
- BIIB 3.36
- 52 Week Low
- EXPE $126.46
- BIIB $110.04
- 52 Week High
- EXPE $213.00
- BIIB $207.59
- Technical
- Relative Strength Index (RSI)
- EXPE 70.26
- BIIB 62.98
- Support Level
- EXPE $181.58
- BIIB $127.00
- Resistance Level
- EXPE $210.83
- BIIB $135.38
- Average True Range (ATR)
- EXPE 6.74
- BIIB 4.29
- MACD
- EXPE 2.17
- BIIB 0.82
- Stochastic Oscillator
- EXPE 85.73
- BIIB 98.39
About EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.